Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.
Saved in:
| Title: | Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. |
|---|---|
| Authors: | Overgaard RV; Novo Nordisk A/S, Søborg, Denmark., Hertz CL; Novo Nordisk A/S, Søborg, Denmark., Ingwersen SH; Novo Nordisk A/S, Søborg, Denmark., Navarria A; Novo Nordisk A/S, Søborg, Denmark., Drucker DJ; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada. |
| Source: | Cell reports. Medicine [Cell Rep Med] 2021 Sep 03; Vol. 2 (9), pp. 100387. Date of Electronic Publication: 2021 Sep 03 (Print Publication: 2021). |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med |
| Database: | MEDLINE Ultimate |
| ISSN: | 2666-3791 |
|---|---|
| DOI: | 10.1016/j.xcrm.2021.100387 |
